Insilico Medicine Selects AI Designed Obesity Drug Candidate ISM1354
Insilico Medicine selected ISM1354 as a preclinical small molecule candidate targeting GIPR for potential treatment of obesity and related conditions. The company announced the selection in a press release.
Insilico used its Chemistry42 platform to generate and optimize molecules for potency, selectivity, and safety. The process included a drug induced liver injury prediction model, affinity ranking, and repeated testing with experimental feedback.
In preclinical studies, ISM1354 showed oral bioavailability of 75% to 104% across mice, rats, dogs, and monkeys. Insilico said the compound produced at least 18 fold greater plasma exposure than a clinical stage benchmark at the same dose and showed weaker inhibition of the OATP1B1 transporter.
The compound had minimal effects on human and monkey liver cell viability at concentrations up to 200 micromolar. A monkey toxicology assessment found no significant toxicity and indicated an estimated safety margin of about 45 fold, supporting further toxicology studies.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Nov 17 Astromech acquires Form Bio in $230 million all-stock deal Nov 17 The Rx Assistant launches Builder, a no-code platform for pharma AI experiences Nov 17 Isomorphic Labs raises $5 billion Series C for AI drug design Nov 17 OpenAI says its computer-use agents can handle clinicians' EHR tasks, with CVS Health and Cigna among users Nov 16 FDA starts calling AI 'Super Intelligence' under Trump executive orderLife AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Whitepaper
Tensordyne Napier: What If One Rack Could Do the Work of Nine?
Tensordyne
This Tensordyne whitepaper presents Napier, an inference-focused AI processor and rack-scale system based on the company’s TDN Math logarithmic number system. It examines infrastructure requirements for large mixture-of-experts and agentic models, compares major inference architecture approaches, and details the TDN AIP processor, TDN72 pod, TDN Link fabric, and Napier Ultra configuration. The paper reports simulation-based performance, cost, and accuracy-validation results, including Tensordyne’s projected comparison of one Napier rack with a nine-rack Nvidia Rubin plus Groq deployment; the chip is reported as taped out and in fabrication.
Read moreYou may also like
Isomorphic Labs raises $5 billion Series C for AI drug design
Isomorphic Labs Seeks $5 Billion at $50 Billion Valuation
iReprogram and University of Michigan Launch AI Diabetes Cell Initiative
Inovia Bio Launches Falcon for Drug Development Workflows
Adsilico Raises £10 Million for Virtual Medical Device Testing
Daily AI Brief: the AI news that matters, in your inbox.